Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

1568.40 55.60 (3.68%)

41.42% Gain from 52W Low

1.4M NSE+BSE Volume

NSE 05 Jun, 2025 12:16 PM (IST)

2

Broker 1Year buys

2 active buys

1

Broker 1Year sells

1 active sells

1

Broker 1Year neutral

1 active holds

Glenmark Pharmaceuticals Ltd. share price target

Glenmark Pharmaceuticals Ltd. has an average share price target of 1662.25. The consensus estimate represents an upside of 5.98% from the last price of 1568.40. View 10 reports from 5 analysts offering long-term price targets for Glenmark Pharmaceuticals Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	05 Jun 2025	Glenmark Pharma	Consensus Share Price Target	1568.40	1678.42	-	7.01	buy	pdf Detailed Estimates
	23 May 2023	Glenmark Pharma	Prabhudas Lilladhar Reco Target	1568.40	570.00	609.00 (157.54%)		Sell	pdf post cache		Broker Report GLENMARK PHARMACEUTI Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2023	Glenmark Pharma	KRChoksey Reco Target	1568.40	683.00	606.00 (158.81%)	Target met	Buy	pdf post cache		Broker Report India business continue to outpace the overall industry KRChoksey Glenmark Pharma performance impacted during the quarter due to subdued performance in the India Business. Factors such as divestment of a few non-core brands ( Razel and other dermatology assets), price revision at NLEM, and returns of COVID-related products, has an affect on the India business, resulted in decline of quarterly revenue to INR 8,284 mn (-6.4% YoY, -22.9% QoQ). pdf Copy Link Share on Share on Share on Share on Alert
	22 May 2023	Glenmark Pharma	ICICI Direct Target	1568.40	580.00	606.00 (158.81%)		Hold	pdf post cache		Broker Report Glenmark Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	22 May 2023	Glenmark Pharma	ICICI Securities Limited Reco Target	1568.40	575.00	606.00 (158.81%)		Sell	pdf post cache		Broker Report Ryaltris drives traction across markets ICICI Securities Limited Glenmark Pharma’s (Glenmark) Q4FY23 revenue growth of 12% YoY was driven by launch of Rylatris across the UK, Asia and RoW markets. Nevertheless, the company’s gross margins contracted 119bps YoY due to cost pressures in India and base price erosion in the US. pdf Copy Link Share on Share on Share on Share on Alert
	16 Feb 2023	Glenmark Pharma	ICICI Securities Limited Target	1568.40	525.00	435.15 (260.43%)	Target met	Buy	pdf post cache		Broker Report RoW and EU markets drive beat ICICI Securities Limited Glenmark Pharma’s (Glenmark) Q3FY23 performance was a beat vs our estimates, largely driven by better than expected RoW and EU performances. Revenue was up 9.2% YoY to Rs34.6bn (I-Sec: Rs31.4bn) led by healthy growth in the US, RoW and EU businesses. pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2023	Glenmark Pharma	Motilal Oswal	1568.40	420.00	422.60 (271.13%)	Target met	Neutral	pdf post cache		Broker Report Financial leverage/tax outweighs operational improvements Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2023	Glenmark Pharma	ICICI Direct Target	1568.40	440.00	422.60 (271.13%)	Target met	Hold	pdf post cache		Broker Report Glenmark Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	21 Nov 2022	Glenmark Pharma	ICICI Direct Target	1568.40	470.00	422.40 (271.31%)	Target met	Hold	pdf post cache		Broker Report Glenmark Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	19 Nov 2022	Glenmark Pharma	Prabhudas Lilladhar Target	1568.40	460.00	411.65 (281.00%)	Target met	Accumulate	pdf post cache		Broker Report GLENMARK PHARMACEUTI Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	17 Nov 2022	Glenmark Pharma	Motilal Oswal	1568.40	420.00	409.85 (282.68%)	Target met	Neutral	pdf post cache		Broker Report Working on many fronts to better outlook and return ratios Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners